CytoReason
CytoReason is an AI-powered biopharma analytics platform that helps researchers and executives optimize drug development decisions. The company has raised $100M, including a Series B in July 2024 with backing from Pfizer and NVIDIA.
The growth story
CytoReason grew from 51 to 107 employees between 2021 and 2026, raising $100M along the way, most recently a Series B in July 2024.
About
CytoReason builds computational disease models that map human biology at cellular resolution, used by drug researchers to identify targets, prioritize indications, and stratify patients. Its platform serves scientists, program leaders, and executives across the drug development lifecycle.
The 107-person company draws heavily from Israel's academic and military tech talent pool, with 25% of analyzed staff coming from Tel Aviv University and 12% from the Weizmann Institute. Its $100M funding includes strategic investors like Pfizer, suggesting industry validation of its approach.
Founders and leadership
Research dominates CytoReason's workforce with 15 identified researchers, reflecting its academic roots in computational biology. The company maintains strong ties to Israel's defense and intelligence sectors, with multiple hires from Unit 8200.
The CytoReason org chart
David H. (Co-Founder and CEO) leads 44 mapped leaders with 6 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 24 (-17% YoY), Engineering 15 (-21% YoY), Healthcare Services 14 (-7% YoY), Information Technology 13 (-13% YoY), Business Development 11 (-8% YoY), Product Management 6 (-14% YoY).
Talent flow
CytoReason recruits heavily from Israel's top STEM programs, with 25% of analyzed staff from Tel Aviv University and another 12% each from Technion and Weizmann Institute. Alumni frequently move to genomics and AI-driven biotech startups like Ultima Genomics and Immunai.
Most common previous employers of CytoReason staff: Weizmann Institute of Science (12), Tel Aviv University (12), Technion - Israel Institute of Technology (11), Israel Defense Forces (5), Israeli Military Intelligence - Unit 8200 (5), Ben-Gurion University of the Negev (5). Former CytoReason employees most often moved to Ultima Genomics (4), Immunai (3), Phylo (3), Promise Bio (3), QED Science (2), Aidoc (2).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at CytoReason: Python (Programming Language) (33), Research Skills (27), R (Programming Language) (26), Molecular Biology (26), Management (24), Bioinformatics (24), SQL (24), Cell Culture (23).
Where the team actually sits
CytoReason people are concentrated in Israel (35), Tel Aviv District, Israel (32), Center District, Israel (14), Haifa District, Israel (2).
Search footprint
CytoReason attracts about 59 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 3 ranking keywords and lost 4 in the last period.
What employees say
- Compensation
- 3.60 / 5
- Career opportunities
- 4.00 / 5
- Senior management
- 3.70 / 5
- Work-life balance
- 4.40 / 5
Frequently asked
CytoReason has 107 employees as of September 2026.
CytoReason has raised $100M in total, most recently a Series B round in July 2024.
CytoReason was founded in 2016 by Shai Shen-Orr, David H..
David H. (Co-Founder and CEO) sits at the top of CytoReason's reporting structure, with 6 direct reports.
The most common previous employers of current CytoReason staff are Weizmann Institute of Science (12 people), Tel Aviv University (12 people), Technion - Israel Institute of Technology (11 people).
Former CytoReason employees most often move to Ultima Genomics (4), Immunai (3), Phylo (3).
CytoReason attracts about 59 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among CytoReason staff are Python (Programming Language), Research Skills, R (Programming Language), Molecular Biology, Management.
CytoReason staff are concentrated in Israel (35), Tel Aviv District, Israel (32), Center District, Israel (14).
CytoReason has about 24 people in Research, down 17% over the past year, as of September 2026.
CytoReason has about 15 people in Engineering, down 21% over the past year, as of September 2026.
Computed from 96 current and 109 former CytoReason profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.